Precision Molecular Pathology of Prostate Cancer

Written by experts in the field Provides the latest information and current insights
Comprehensively covers the new molecular pathology of prostate cancer

Written by experts in the field Provides the latest information and current insights Comprehensively covers the new molecular pathology of prostate cancer

Auteur
Brian D. Robinson, MD
Weill Cornell MedicineNew York, NYUSA

Contenu
Part I. General principles.- Approach to patient.- Etiology.- Precursor and pre-invasive lesions of prostate cancer.- Prostatic adenocarcinoma: morphologic spectrum, Gleason scoring, etc.- Genetic susceptibility.- DNA damage repair, BRCA mutations, DNA adducts, SNPs.- Racial differences.- Cancer stem cells Part II. Molecular signatures of primary prostate cancer.- SNPs.- Copy number variation/chromosomal aberration (PTEN deletion, etc.).- Gene fusions (TMPRSS2:ERG, etc.).- Gene expression arrays.- Next generation sequencing (point mutations, indels, etc.).- Epigenetic changes (chromatin remodeling, etc.).- Proteomics.- Metabolomics.- miRNA and lncRNA Part III. Molecular signatures of advanced prostate cancer.- Lymph node metastasis.- Bone metastasis a.- RANKL, Src kinases, endothelins, bisphosphonates.- Visceral metastasis a.- Role of extracellular matrix, angiogenesis, epithelial-mesenchymal transition (EMT), inflammation.- Castration resistant prostate cancer (CRPC).- Neuroendocrineprostate cancer (NEPC) Part IV. Key molecular pathways in prostate cancer development and progression.- Androgen receptor in carcinogenesis.- Androgen receptor in progression (CRPC).- PI3K/Akt/mTOR/PTEN and ERK/MAPK pathways.- Cell cycle regulators (p53, etc.).- DNA damage repair.- Tyrosine kinase signaling (EGFR, VEGFR, PDGFR, FGFR, IGFR, etc.).- Cytoskeletal function (microtubules and taxane therapy) Part V. Precision medicine approach: Diagnosis, treatment, prognosis.- Molecular diagnosis.- Molecular imaging.- Molecular prognostic markers/tests.- Molecular targeted therapies.- Towards molecular classification of prostate cancer.